Literature DB >> 20357099

Murine coronavirus delays expression of a subset of interferon-stimulated genes.

Kristine M Rose1, Ruth Elliott, Luis Martínez-Sobrido, Adolfo García-Sastre, Susan R Weiss.   

Abstract

The importance of the type I interferon (IFN-I) system in limiting coronavirus replication and dissemination has been unequivocally demonstrated by rapid lethality following infection of mice lacking the alpha/beta IFN (IFN-alpha/beta) receptor with mouse hepatitis virus (MHV), a murine coronavirus. Interestingly, MHV has a cell-type-dependent ability to resist the antiviral effects of IFN-alpha/beta. In primary bone-marrow-derived macrophages and mouse embryonic fibroblasts, MHV replication was significantly reduced by the IFN-alpha/beta-induced antiviral state, whereas IFN treatment of cell lines (L2 and 293T) has only minor effects on replication (K. M. Rose and S. R. Weiss, Viruses 1:689-712, 2009). Replication of other RNA viruses, including Theiler's murine encephalitis virus (TMEV), vesicular stomatitis virus (VSV), Sindbis virus, Newcastle disease virus (NDV), and Sendai virus (SeV), was significantly inhibited in L2 cells treated with IFN-alpha/beta, and MHV had the ability to rescue only SeV replication. We present evidence that MHV infection can delay interferon-stimulated gene (ISG) induction mediated by both SeV and IFN-beta but only when MHV infection precedes SeV or IFN-beta exposure. Curiously, we observed no block in the well-defined IFN-beta signaling pathway that leads to STAT1-STAT2 phosphorylation and translocation to the nucleus in cultures infected with MHV. This observation suggests that MHV must inhibit an alternative IFN-induced pathway that is essential for early induction of ISGs. The ability of MHV to delay SeV-mediated ISG production may partially involve limiting the ability of IFN regulatory factor 3 (IRF-3) to function as a transcription factor. Transcription from an IRF-3-responsive promoter was partially inhibited by MHV; however, IRF-3 was transported to the nucleus and bound DNA in MHV-infected cells superinfected with SeV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20357099      PMCID: PMC2876584          DOI: 10.1128/JVI.00211-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production.

Authors:  J M Emeny; M J Morgan
Journal:  J Gen Virol       Date:  1979-04       Impact factor: 3.891

Review 2.  Stats: multifaceted regulators of transcription.

Authors:  Melissa M Brierley; Eleanor N Fish
Journal:  J Interferon Cytokine Res       Date:  2005-12       Impact factor: 2.607

3.  Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation.

Authors:  Wataru Kamitani; Krishna Narayanan; Cheng Huang; Kumari Lokugamage; Tetsuro Ikegami; Naoto Ito; Hideyuki Kubo; Shinji Makino
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-15       Impact factor: 11.205

4.  Protective effects of murine recombinant interferon-beta administered by intravenous, intramuscular or subcutaneous route on mouse hepatitis virus infection.

Authors:  S Matsuyama; S Henmi; N Ichihara; S Sone; T Kikuchi; T Ariga; F Taguchi
Journal:  Antiviral Res       Date:  2000-08       Impact factor: 5.970

5.  Characterization of the elements and proteins responsible for interferon-stimulated gene induction by human cytomegalovirus.

Authors:  Shaojun Yang; James Netterwald; Weijia Wang; Hua Zhu
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist.

Authors:  Ye Ye; Kevin Hauns; Jeffrey O Langland; Bertram L Jacobs; Brenda G Hogue
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

7.  Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3.

Authors:  Martin Spiegel; Andreas Pichlmair; Luis Martínez-Sobrido; Jerome Cros; Adolfo García-Sastre; Otto Haller; Friedemann Weber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  MDA5 participates in the detection of paramyxovirus infection and is essential for the early activation of dendritic cells in response to Sendai Virus defective interfering particles.

Authors:  Jacob S Yount; Leonid Gitlin; Thomas M Moran; Carolina B López
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

9.  Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells.

Authors:  Derek D C Ireland; Stephen A Stohlman; David R Hinton; Roscoe Atkinson; Cornelia C Bergmann
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

10.  Synergistic antiviral effect of a combination of mouse interferon-alpha and interferon-gamma on mouse hepatitis virus.

Authors:  Uichiro Fuchizaki; Shuichi Kaneko; Yasunari Nakamoto; Yoshihiro Sugiyama; Kenichi Imagawa; Mikio Kikuchi; Kenichi Kobayashi
Journal:  J Med Virol       Date:  2003-02       Impact factor: 2.327

View more
  32 in total

1.  Cell-type-specific type I interferon antagonism influences organ tropism of murine coronavirus.

Authors:  Ling Zhao; Kristine M Rose; Ruth Elliott; Nico Van Rooijen; Susan R Weiss
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  The nsp1, nsp13, and M proteins contribute to the hepatotropism of murine coronavirus JHM.WU.

Authors:  Rong Zhang; Yize Li; Timothy J Cowley; Adam D Steinbrenner; Judith M Phillips; Boyd L Yount; Ralph S Baric; Susan R Weiss
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

3.  Endoplasmic reticulum stress regulates the innate immunity critical transcription factor IRF3.

Authors:  Yi-Ping Liu; Ling Zeng; Austin Tian; Ashley Bomkamp; Daniel Rivera; Delia Gutman; Glen N Barber; Julie K Olson; Judith A Smith
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

4.  Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required for Resistance to Innate Immunity.

Authors:  James Brett Case; Yize Li; Ruth Elliott; Xiaotao Lu; Kevin W Graepel; Nicole R Sexton; Everett Clinton Smith; Susan R Weiss; Mark R Denison
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

Review 5.  COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors:  Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal:  Front Microbiol       Date:  2020-12-01       Impact factor: 5.640

6.  Activation of the chicken type I interferon response by infectious bronchitis coronavirus.

Authors:  Joeri Kint; Marcela Fernandez-Gutierrez; Helena J Maier; Paul Britton; Martijn A Langereis; Joseph Koumans; Geert F Wiegertjes; Maria Forlenza
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

7.  Simian varicella virus inhibits the interferon gamma signalling pathway.

Authors:  Werner J D Ouwendijk; Suzanne van Veen; Ravi Mahalingam; Georges M G M Verjans
Journal:  J Gen Virol       Date:  2017-10       Impact factor: 3.891

8.  Cell-type-specific activation of the oligoadenylate synthetase-RNase L pathway by a murine coronavirus.

Authors:  Ling Zhao; L Dillon Birdwell; Ashley Wu; Ruth Elliott; Kristine M Rose; Judith M Phillips; Yize Li; Judith Grinspan; Robert H Silverman; Susan R Weiss
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

9.  Rescue of recombinant Newcastle disease virus from cDNA.

Authors:  Juan Ayllon; Adolfo García-Sastre; Luis Martínez-Sobrido
Journal:  J Vis Exp       Date:  2013-10-11       Impact factor: 1.355

10.  Infectious Bronchitis Coronavirus Inhibits STAT1 Signaling and Requires Accessory Proteins for Resistance to Type I Interferon Activity.

Authors:  Joeri Kint; Annemiek Dickhout; Jasmin Kutter; Helena J Maier; Paul Britton; Joseph Koumans; Gorben P Pijlman; Jelke J Fros; Geert F Wiegertjes; Maria Forlenza
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.